Anavex Life Sciences Corp.

Subtitles by the Amara.org community

You have the recommendation for each of the three studies. The recommendation is to continue the studies without modifications. This is very good news and indicates we are on the right path with all these studies. As a reminder, Our clinical strategy is to clearly differentiate from other biopharma companies in clinical studies in CNS. Anavex is continuing to pioneer the approach of big data, including omics in clinical trials to leverage the level of phenotypic and genotypic precision medicine analysis. of whole genome sequencing and gene expression data in drug development, and in particular, the potential to identify patients' genetic variants and gene expression changes that may predict increased chance of success for Rett syndrome, Parkinson's disease, and Alzheimer's disease treatments. And now, I would like to direct the call to Sandra Boenisch, Principal Financial Officer of Anavex for a brief financial summary of the recently reported quota.

Thank you, Christopher, and good afternoon, everyone. We continue to apply fiscally responsible management of cash utilization with moderate increases within budget. We reported a net loss of $8.2 million for the quarter, or $0.12 per share, as compared to $7.2 million also 12 cents per share in the comparable quarter of last year. Research and development expenses were $6.7 million for the quarter compared to $6.1 million for the comparable quarter of fiscal 2020. The increase is primarily attributable to the continued advancement of our ongoing clinical trial. General and administrative expenses were $2.2 million for the quarter as compared to $1.7 million for the prior year period. The increase is associated with the growth of our team. Our cash position on March 31st, 2021 was 75.9 million, which we believe is sufficient cash runway for up to three years. Thank you, and I will now turn the call back over to Dr. Misling.